Viridian Therapeutics, Inc.

VRDN · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$34,599-$100,735-$86,912-$79,725
Dep. & Amort.$110$113$117$123
Deferred Tax$0$0$0$0
Stock-Based Comp.$11,250$10,844$10,220$8,975
Change in WC-$60,328$15,865-$13,855$460
Other Non-Cash-$1,044-$1,460-$2,223-$3,165
Operating Cash Flow-$84,611-$75,373-$92,653-$73,332
Investing Activities
PP&E Inv.-$127-$42-$86-$114
Net Acquisitions$0$0$0$0
Inv. Purchases-$14,086-$55,755-$71,243-$181,779
Inv. Sales/Matur.$140,290$131,515$171,391$118,978
Other Inv. Act.$0$0$0$0
Investing Cash Flow$126,077$75,718$100,062-$62,915
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$9,960$1$4,943$33,646
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$897$763$4,269$1,878
Financing Cash Flow$10,857$764$9,212$35,524
Forex Effect$0$0$0$0
Net Chg. in Cash$52,323$1,109$16,621-$100,723
Supplemental Information
Beg. Cash$117,324$116,215$99,594$200,317
End Cash$169,647$117,324$116,215$99,594
Free Cash Flow-$84,738-$75,415-$92,739-$73,446